Hepatitis B and Liver Fibrosis - Staging with Elastography
Chronic hepatitis B remains one of the key liver conditions where fibrosis staging changes management. Elastography is useful here because it supports non-invasive assessment over time, but the interpretation rules are not identical to MAFLD.
Content note
Prepared by the Elastography Australia clinical education team for informational purposes and pathway literacy. It is not patient-specific medical advice.
- HBV staging requires disease-specific interpretation rather than simply reusing MAFLD assumptions.
- Inflammatory activity can affect stiffness, which is why ALT and clinical context matter.
- Serial non-invasive monitoring is often more practical than relying on biopsy pathways alone.
HBV in Australia
Hepatitis B remains an important liver disease burden in Australia, particularly in communities where chronic infection prevalence and long-term surveillance needs remain significant.
For clinicians, the value of elastography is that it helps estimate fibrosis without pushing every patient toward invasive investigation when the real need is structured long-term monitoring.
How staging differs from MAFLD
HBV is not just another fibrosis pathway. Stiffness interpretation changes because inflammatory activity and viral disease context can shift readings in ways that do not map cleanly onto metabolic disease algorithms.
That is why the playbook specifically calls out CHB-specific kPa interpretation and guideline-led use rather than one universal cut-off model.
ALT confounding and timing
ALT flares and inflammatory activity can raise liver stiffness independently of fibrosis burden. In practical terms, this means the clinician must interpret the scan in the context of disease activity and not as an isolated number.
Used carefully, serial elastography can still be valuable for long-term trend assessment and treatment follow-up.
When fibrosis staging changes management
Fibrosis burden influences treatment decisions, specialist urgency, and surveillance planning. A non-invasive test that can be repeated over time is especially helpful where clinicians want to observe regression or progression without repeated biopsy decisions.